Carl Zeiss has finally reached an agreement with Asclepion-Meditec over the valuation of their respective activities, which has been contested by some shareholders. Zeiss will end up owning 76 percent of the new company that will combine its own ophthalmic business with Asclepion, provided the deal is approved at the ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.